1. Home
  2. TUYA vs SNDX Comparison

TUYA vs SNDX Comparison

Compare TUYA & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TUYA
  • SNDX
  • Stock Information
  • Founded
  • TUYA 2014
  • SNDX 2005
  • Country
  • TUYA China
  • SNDX United States
  • Employees
  • TUYA N/A
  • SNDX N/A
  • Industry
  • TUYA Computer Software: Prepackaged Software
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • TUYA Technology
  • SNDX Health Care
  • Exchange
  • TUYA Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • TUYA 1.2B
  • SNDX 1.3B
  • IPO Year
  • TUYA 2021
  • SNDX 2016
  • Fundamental
  • Price
  • TUYA $2.21
  • SNDX $19.91
  • Analyst Decision
  • TUYA Strong Buy
  • SNDX Strong Buy
  • Analyst Count
  • TUYA 1
  • SNDX 12
  • Target Price
  • TUYA $3.49
  • SNDX $36.92
  • AVG Volume (30 Days)
  • TUYA 969.4K
  • SNDX 3.0M
  • Earning Date
  • TUYA 11-24-2025
  • SNDX 11-03-2025
  • Dividend Yield
  • TUYA 4.89%
  • SNDX N/A
  • EPS Growth
  • TUYA N/A
  • SNDX N/A
  • EPS
  • TUYA 0.08
  • SNDX N/A
  • Revenue
  • TUYA $319,363,000.00
  • SNDX $111,304,000.00
  • Revenue This Year
  • TUYA $10.16
  • SNDX $636.61
  • Revenue Next Year
  • TUYA $12.68
  • SNDX $114.95
  • P/E Ratio
  • TUYA $28.75
  • SNDX N/A
  • Revenue Growth
  • TUYA 13.66
  • SNDX 595.65
  • 52 Week Low
  • TUYA $1.57
  • SNDX $8.58
  • 52 Week High
  • TUYA $4.63
  • SNDX $20.08
  • Technical
  • Relative Strength Index (RSI)
  • TUYA 49.62
  • SNDX 72.56
  • Support Level
  • TUYA $2.01
  • SNDX $16.75
  • Resistance Level
  • TUYA $2.38
  • SNDX $20.08
  • Average True Range (ATR)
  • TUYA 0.11
  • SNDX 1.23
  • MACD
  • TUYA 0.03
  • SNDX 0.40
  • Stochastic Oscillator
  • TUYA 55.13
  • SNDX 97.58

About TUYA Tuya Inc. each representing one

Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers innovative physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It also provides a complete, open, and neutral global AIoT ecosystem. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: